Malika Ammor, NP
Nurse Practitioner · Framingham, MANPI 1942828835
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Merz North America, Inc. at 57.6% of the total. 2025 is the largest year on record at $5,959, more than ten times the $11 reported in 2021. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $59.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$5K
- Johnson & Johnson$395
- Exelixis Inc.$357
- Astellas Pharma US Inc$317
- Bristol Myers Squibb$254
- Pfizer$217
- plus $2K from 30 others
What the payments were for
- Travel & lodging$2,56232%
- Food & beverage$4,56357%
- Education$83210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 32 | $4,587 |
| Johnson & Johnson(2 entities) | 9 | $395 |
| Exelixis Inc. | 7 | $357 |
| Astellas Pharma US Inc | 5 | $317 |
| Bristol Myers Squibb | 9 | $254 |
| Pfizer | 8 | $217 |
| AstraZeneca(2 entities) | 7 | $194 |
| Revance Therapeutics, Inc. | 3 | $145 |
| AbbVie | 2 | $140 |
| Gilead(2 entities) | 5 | $138 |
| Merck | 4 | $115 |
| Bayer | 5 | $111 |
| Regeneron Healthcare Solutions, Inc. | 1 | $99 |
| Novartis | 3 | $95 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| ADC Therapeutics America, Inc. | 3 | $64 |
| Daiichi Sankyo Inc. | 2 | $59 |
| Eisai Inc. | 2 | $55 |
| Sanofi | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| GSK | 2 | $47 |
| Tempus AI, Inc | 2 | $45 |
| Legend Biotech USA Inc. | 2 | $36 |
| Beigene USA, Inc. | 1 | $34 |
| Genentech USA, Inc. | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $27 |
| Acrotech Biopharma Inc. | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| CTI Biopharma Corp. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,958 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 20 | $460,519 |
| RevlimidLenalidomide | 21 | $330,249 |
| Lenalidomide | 28 | $309,129 |
| JakafiRuxolitinib Phosphate | 17 | $230,815 |
| TagrissoOsimertinib Mesylate | 11 | $182,219 |
| BrukinsaZanubrutinib | 16 | $104,669 |
| EliquisApixaban | 51 | $53,956 |
| Abiraterone Acetate | 12 | $15,205 |
| Exemestane | 13 | $6,094 |
| Hydroxyurea | 27 | $1,821 |
| Anastrozole | 35 | $1,430 |
| Acyclovir | 38 | $844 |
| Alendronate Sodium | 31 | $351 |
| Tamoxifen Citrate | 12 | $336 |
| Letrozole | 11 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $70 | $460,51920 claims |
| Bristol Myers SquibbRevlimid | $254 | $330,24921 claims |
| AstraZenecaTagrisso | $194 | $182,21911 claims |
| Beigene USA, Inc.Brukinsa | $34 | $104,66916 claims |
| PfizerEliquis | $217 | $53,95651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Framingham
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
- Lauren BurkeBoston$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.